Article Text

Download PDFPDF
Gene therapy for neuromuscular disorders: prospects and ethics
  1. Monique M Ryan1,2
  1. 1 Children's Neurosciences Centre, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
  2. 2 Murdoch Children's Research Institute, Parkville, Victoria, Australia
  1. Correspondence to Dr Monique M Ryan, Children's Neurosciences Centre, The Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia; monique.ryan{at}rch.org.au

Abstract

Most childhood neuromuscular disorders are caused by mutations causing abnormal expression or regulation of single genes or genetic pathways. The potential for gene therapy, gene editing and genetic therapies to ameliorate the course of these conditions is extraordinarily exciting, but there are significant challenges associated with their use, particularly with respect to safety, efficacy, cost and equity. Engagement with these novel technologies mandates careful assessment of the benefits and burdens of treatment for the patient, their family and their society. The examples provided by spinal muscular atrophy and Duchenne muscular dystrophy illustrate the potential value and challenges of gene and genetic therapies for paediatric neurological conditions. The cost and complexity of administration of these agents is a challenge for all countries. Jurisdictional variations in availability of newborn screening, genetic diagnostics, drug approval and reimbursement pathways, treatment and rehabilitation will affect equity of access, nationally and internationally. These challenges will best be addressed by collaboration by governments, pharma, clinicians and patient groups to establish frameworks for safe and cost-effective use of these exciting new therapies.

  • neurology
  • genetics
  • therapeutics
  • ethics

Data availability statement

No data are available. This is an invited review with no original data.

Statistics from Altmetric.com

Data availability statement

No data are available. This is an invited review with no original data.

View Full Text

Footnotes

  • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.